7 March 2014

Antisense Therapeutics to Present at ROTH Capital Partners 26th Annual Growth Stock Conference: 9th – 12th March 2014

Antisense Therapeutics Ltd. (ASX:ANP) announced today that Chief Executive Officer and Managing Director, Mark Diamond, has been invited to present an overview of the company and it's development pipeline at the ROTH Capital Partners 26th Annual Growth Stock Conference, Ritz-Carlton, Laguna Niguel, California, USA on Wednesday 12th March at 11.00am (California USA time).

The presentation and a live webcast may be accessed on the following link:

http://wsw.com/webcast/roth28/anp.ax

The webcast can also be accessed via the Company's website, www.antisense.com.au. A replay of the presentation will be archived for 90 days after the conference, at the same location.

About ROTH Capital Partners Conference: One of the largest of its kind, ROTH's flagship three-day investment conference brings together executives from more than 450 public and private companies and approximately 1,000 investors. The event provides attendees with investment ideas across a variety of sectors, including Business Services, Consumer, Cleantech, Energy & Industrials, Healthcare, Oil and Gas, Mining, and Technology & Media. Company presentations, Q&A sessions, panels and management one-on-one meetings offer investor clients opportunities for extensive interaction with executive management to gain in-depth insights into each business and sector.

Antisense Therapeutics Limited (ASX: ANP) is an Australian publicly listed biopharmaceutical drug discovery and development company. Its mission is to create, develop and commercialise second generation antisense pharmaceuticals for large unmet markets. ANP has 4 products in its development pipeline that it has in-licensed from Isis Pharmaceuticals Inc., world leaders in antisense drug development and commercialisation - ATL1102 (injection) which has successfully completed a Phase II efficacy and safety trial, significantly reducing the number of brain lesions in patients with multiple sclerosis (MS) and has entered clinical development as a stem cell mobilisation agent, ATL1103 a second-generation antisense drug designed to block GHr production and thereby lower blood IGF-I levels and is in clinical development as a potential treatment for growth and other GH-IGF-I disorders, ATL1102 (inhaled) which is at the pre-clinical research stage as a potential treatment for asthma and ATL1101 a second-generation antisense drug at the pre-clinical stage being investigated as a potential treatment for cancer.

Contact Information:
Website: www.antisense.com.au
Managing Director: Mark Diamond +61 (3) 9827 8999
USA Investor/Media: Joshua Drumm +(1) 212 375 2664; jdrumm@tiberend.com
Australia Investor/Media: Simon Watkin +61 (0)413 153 272; simon@marketconnect.com.au